Four settlement agreements with several Defendants named in the Opioid Class Action (the “Settling Defendants”) have been reached:
1) an agreement with Roxane Laboratories Inc. and Boehringer Ingelheim (Canada) Ltd. that provides for a full and final release of all claims against them, as well as against Hikma Labs Inc., in exchange for the payment of CAD $125,000 (the “R&B Settlement”),
2) an agreement with BGP Pharma ULC and Mylan Pharmaceuticals ULC that provides for the full and final release from all claims against them in exchange for the payment of USD $199,000 (the “B&M Settlement”);
3) an agreement with Merck Frosst Canada & Co. (“MFC”) that provides for the full and final release from all claims against it in exchange for the payment of CAD $145,000 (the “MFC Settlement”); and
4) an agreement with Sanis Health Inc. (“Sanis”) that provides for the full and final release from all claims against it in exchange for the payment of CAD $180,000 (the “Sanis Settlement”)
(collectively, the “Settlement Agreements”).
The Settlement Agreements allow the Plaintiff to continue the Opioid Class Action against the remaining Defendants, excluding the Settling Defendants and Hikma Labs Inc.
The Settlement Agreements are available here.
The complete notice to class members is available here.
